FDA-approved CD34+ stem cell enrichment for leukemia research
Hematopoietic stem cell transplantation (HSCT) based on CD34+ cell enrichment
The CD34 antigen is expressed on early hematopoietic progenitor cells. Investigative studies with the CliniMACS® System have shown that CD34+ peripheral blood progenitor cells reconstitute all hematopoietic cell lineages when infused after myeloablative chemotherapy.1
Enrichment of CD34+ stem cells for leukemia research on the CliniMACS Plus
The CliniMACS CD34 Reagent System takes advantage of the selectivity of monoclonal CD34 antibodies conjugated to magnetic particles. The CD34-positive target cells are selected in an automated separation process on the CliniMACS Plus Instrument.
For labeling of the CD34+ cells, an apheresis product is incubated with the CliniMACS CD34 Reagent. After washing away the excess unbound reagent the automated selection is started.
The CliniMACS Plus passes the antibody-labeled suspension through a column in which strong magnetic gradients are generated. The column retains the magnetically labeled CD34+ cells while unwanted cells flow through and are collected in the negative fraction bag. The system performs several washing steps that dispose of most of the liquid into the buffer waste bag. After the magnetic field is removed, the selected CD34+ cells are eluted into the cell collection bag.
References
1. Richel D. J. et al. (2000) Highly purified CD34+ cells isolated using magnetically activated cell selection provide rapid engraftment following high-dose chemotherapy in breast cancer patients. Bone Marrow Transplant 25: 243–249.
Humanitarian Device
Authorized by U.S. Federal Law for use in the treatment of patients with acute myeloid leukemia (AML) in first complete remission. The effectiveness of the device for this use has not been demonstrated.
Indications for Use
The CliniMACS® CD34 Reagent System is indicated for processing hematopoietic progenitor cells collected by apheresis (HPC, Apheresis) from an allogeneic, HLA-identical, sibling donor to obtain a CD34+ cell-enriched population for hematopoietic reconstitution following a myeloablative preparative regimen without the need for additional graft versus host disease (GVHD) prophylaxis in patients with acute myeloid leukemia (AML) in first morphologic complete remission.
Contraindications
Do not use CD34+ cells prepared with CliniMACS CD34 Reagent System in patients with known hypersensitivity to murine (mouse) proteins or iron dextran.
Rx only